The Stroke Foundation is a national charity that partners with the community to prevent, treat and beat stroke. We
stand alongside stroke survivors and their families, healthcare professionals and researchers. We build community
awareness and foster new thinking and innovative treatments. We support surv...
Antiplatelet and antithrombotic
medication management before, during, and after
neurointerventional procedures has significant practice
variation. This document updates and builds upon the
2014 Society of NeuroInterventional Surgery (SNIS)
Guideline ’Platelet function inhibitor and platelet
function te...
Cílem tohoto KDP je poskytnout nástroj pro rozhodování o sekundární prevenci ischemické cévní mozkové příhody (iCMP) nebo tranzitorní ischemické ataky (TIA) u pacientů s otevřeným foramen ovale (PFO) a o péči o pacienty s CMP a hypertenzí na základě nejlepších dostupných důkazů...
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
In June 2022, we reviewed the evidence and mad...
In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. This decision was based on new evidence on the ...
This guideline covers investigation and management of heart valve disease presenting in adults. It
aims to improve quality of life and survival for people with heart valve disease through timely
diagnosis and appropriate intervention....
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications. In December 2020, we made minor changes to the ...
Diabetes Mellitus, Type 2/drug therapy,
Diabetes Mellitus, Type 2/prevention & control,
Patient Education as Topic,
Glucose/analysis,
Eye-Tracking Technology,
Dipeptidyl-Peptidase IV Inhibitors/therapeutic use,
Pioglitazone/therapeutic use,
Sulfonylurea Compounds/therapeutic use,
Platelet Aggregation Inhibitors/therapeutic use
This guideline covers the assessment and early management of head injury in children, young people and adults. It promotes effective clinical assessment so that people receive the right care for the severity of their head injury, including referral directly to specialist care if needed. In September 2019...
Macle, L;
Cairns, J;
Leblanc, K;
Tsang, T;
Skanes, A;
Cox, JL;
Healey, JS;
Bell, A;
Pilote, L;
Andrade, JG;
Mitchell, LB;
Atzema, C;
Gladstone, D;
Sharma, M;
Verma, S;
Connolly, S;
Dorian, P;
Parkash, R;
Talajic, M;
Nattel, S;
Verma, A.
The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the management of antithrombotic therapy for AF pa...
Anticoagulants,
Cardiotonic Agents,
Platelet Aggregation Inhibitors,
Digoxin,
Magnesium,
Acute Coronary Syndrome/therapy,
Algorithms,
Anticoagulants/therapeutic use,
Atrial Appendage/surgery,
Atrial Fibrillation,
Cardiac Pacing, Artificial,
Cardiotonic Agents/adverse effects,
Catheter Ablation,
Cardiotonic Agents/administration & dosage,
Atrial Fibrillation/therapy,
Atrial Fibrillation/complications,
Hemorrhage/chemically induced,
Hemorrhage/prevention & control,
Magnesium/therapeutic use,
Percutaneous Coronary Intervention,
Platelet Aggregation Inhibitors/therapeutic use,
Postoperative Complications/prevention & control,
ST Elevation Myocardial Infarction/therapy,
Stroke/prevention & control,
Coronary Artery Disease/complications,
Digoxin/administration & dosage,
Digoxin/adverse effects,
Drug Therapy, Combination,
Factor Xa Inhibitors/therapeutic use,
Fibrinolytic Agents/therapeutic use,
Factor Xa Inhibitors
This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease....
